Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery

被引：0
|
作者：
Schwenkglenks, M. [1 ]
Pettengell, R. [2 ]
Culakova, E. [3 ]
Lyman, G. H. [3 ]
机构：
[1] Univ Basel, European Ctr Pharmaceut Med, Impact Neutropenia Chemotherapy European Study Gr, Basel, Switzerland
[2] St Georges Univ, Impact Neutropenia Chemotherapy European Study Gr, London, England
[3] Duke Univ, Awareness Neutropenia Chemotherapy Study Grp, Durham, NC USA
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71916-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：567 / 567
页数：1
相关论文
共 50 条
  • [1] Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery
    Matthias Schwenkglenks
    Ruth Pettengell
    Thomas D Szucs
    Eva Culakova
    Gary H Lyman
    Journal of Hematology & Oncology, 3
  • [2] Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery
    Schwenkglenks, Matthias
    Pettengell, Ruth
    Szucs, Thomas D.
    Culakova, Eva
    Lyman, Gary H.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2010, 3
  • [3] Treatment of Hodgkin Lymphoma With ABVD Chemotherapy in Rural Rwanda: A Model for Cancer Care Delivery Implementation
    DeBoer, Rebecca J.
    Shyirambere, Cyprien
    Driscoll, Caitlin D.
    Butera, Yvan
    Paciorek, Alan
    Ruhangaza, Deogratias
    Fadelu, Temidayo A.
    Umwizerwa, Aline
    Bigirimana, Jean Bosco
    Muhayimana, Clemence
    Nguyen, Cam
    Park, Paul H.
    Mpunga, Tharcisse
    Lehmann, Leslie
    Shulman, Lawrence N.
    JCO GLOBAL ONCOLOGY, 2020, 6 : 1093 - 1102
  • [4] Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support
    Nangalia, Jyoti
    Smith, Hannah
    Wimperis, Jennie Z.
    LEUKEMIA & LYMPHOMA, 2008, 49 (08) : 1530 - 1536
  • [5] Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy
    Chand, VK
    Link, BK
    Ritchie, JM
    Shannon, M
    Wooldridge, JE
    LEUKEMIA & LYMPHOMA, 2006, 47 (04) : 657 - 663
  • [6] ABVD CHEMOTHERAPY IN CHILDREN WITH ALL STAGES OF HODGKIN LYMPHOMA
    Sau, A.
    Pascale, S.
    Onofrillo, D.
    Angrilli, F.
    Spadano, A.
    HAEMATOLOGICA, 2019, 104 : 128 - 129
  • [7] Report on the Treatment of Hodgkin Lymphoma with ABVD Chemotherapy at Two Rural District Hospitals in Rwanda
    Shyirambere, Cyprien
    Deboer, Rebecca
    Butera, Yvan
    Driscoll, Caitlin
    Bigirimana, Jean Bosco
    Uwizeye, Francois Regis
    Fadelu, Temidayo
    Park, Paul H.
    Paciorek, Alan
    Lehmann, Leslie E.
    Shulman, Lawrence N.
    BLOOD, 2019, 134
  • [8] Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era
    Azim Jalali
    Francis J. Ha
    Geoff Chong
    Andrew Grigg
    Joe Mckendrick
    Anthony P. Schwarer
    Rowan Doig
    Anis Hamid
    Eliza A. Hawkes
    Annals of Hematology, 2016, 95 : 809 - 816
  • [9] OUTCOME OF ABVD CHEMOTHERAPY IN AN AUSTRALIAN POPULATION OF HODGKIN LYMPHOMA (HL)
    Jalali, A.
    Ha, F.
    Chong, G.
    Grigg, A.
    McKendrick, J.
    Schwarer, A.
    Doig, R.
    Hamid, A.
    Hawkes, E. A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 54 - 54
  • [10] Outcome of ABVD chemotherapy in an Australian population of Hodgkin lymphoma (HL)
    Jalali, A.
    Ha, F.
    Chong, G.
    Grigg, A.
    McKendrick, J.
    Schwarer, A.
    Doig, R.
    Hamid, A.
    Hawkes, E. A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S654 - S654
12345